We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
-22.38%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$174M
AUM Growth
-$35M
Cap. Flow
+$36.4M
Cap. Flow %
20.95%
Top 10 Hldgs %
76.37%
Holding
28
New
9
Increased
8
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
AIMT
Aimmune Therapeutics
AIMT
+$5.94M
2
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$5.5M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$4.95M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$3.55M
5
AMRN
Amarin Corp
AMRN
+$3.24M

Top Sells

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$920K
2
BLU
BELLUS Health Inc.
BLU
+$842K

Sector Composition

Rank Sector Weight
1 Healthcare 97.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ICPT
1
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$25.4M 14.63%
403,688
– –
PRNB
2
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$23.8M 13.71%
401,046
+94,262
+31% +$5.5M
SWTX
3
DELISTED
SpringWorks Therapeutics
SWTX
$16.9M 9.72%
625,281
-28,221
-4% -$920K
ODT
4
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$14.4M 8.3%
522,637
– –
ALLK
5
DELISTED
Allakos
ALLK
$12.1M 6.94%
270,965
+28,460
+12% +$1.95M
STRO icon
6
Sutro Biopharma
STRO
$384M
$11.5M 6.61%
112,558
– –
BCEL
7
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$9.88M 5.68%
596,838
+5,470
+0.9% +$99.2K
SYRS
8
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$9.6M 5.52%
172,660
– –
LQDA icon
9
Liquidia Corp
LQDA
$7.5B
$4.78M 2.75%
1,013,773
+55,307
+6% +$274K
HOOK
10
DELISTED
HOOKIPA Pharma
HOOK
$4.38M 2.52%
53,025
– –
RYTM icon
11
Rhythm Pharmaceuticals
RYTM
$7.44B
$4.21M 2.42%
+276,289
New +$4.95M
TPST icon
12
Tempest Therapeutics
TPST
$15M
$3.97M 2.28%
3,853
+185
+5% +$270K
BLU
13
DELISTED
BELLUS Health Inc.
BLU
$3.92M 2.25%
394,431
-94,427
-19% -$842K
PVLA
14
Palvella Therapeutics
PVLA
$2.02B
$3.69M 2.13%
20,253
+11,450
+130% +$2.89M
AIMT
15
DELISTED
Aimmune Therapeutics
AIMT
$3.35M 1.93%
+232,571
New +$5.94M
ARAV
16
DELISTED
Aravive, Inc. Common Stock
ARAV
$3.32M 1.91%
576,066
– –
ISEE
17
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$2.97M 1.71%
862,552
+162,552
+23% +$950K
ACRS icon
18
Aclaris Therapeutics
ACRS
$732M
$2.71M 1.56%
+2,608,117
New +$3.55M
VIRX
19
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.46M 1.42%
169,663
– –
RCKT icon
20
Rocket Pharmaceuticals
RCKT
$343M
$1.79M 1.03%
+128,197
New +$2.54M
UROV
21
DELISTED
Urovant Sciences Ltd.
UROV
$1.45M 0.84%
157,480
– –
KALV
22
DELISTED
KalVista Pharmaceuticals
KALV
$1.29M 0.74%
168,174
+49,674
+42% +$670K
ATXS
23
DELISTED
Astria Therapeutics
ATXS
$1.25M 0.72%
50,000
– –
BLUE
24
DELISTED
bluebird bio
BLUE
$1.14M 0.66%
+1,914
New +$1.87M
PTLA
25
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1.14M 0.66%
+159,772
New +$1.99M
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q1 2020 Portfolio in Review

As of Q1 2020, Samsara BioCapital held 28 positions worth $174M, down 17% from $209M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Samsara BioCapital deployed $36.4M of net new capital in Q1 2020, opening 9 new positions and adding to 8 existing holdings. Its largest new stake was Aimmune Therapeutics: 232,571 shares worth $3.35M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $920K trimmed.

  • Samsara BioCapital's largest Q1 2020 buy was Aimmune Therapeutics: 232,571 shares worth $3.35M.
  • Samsara BioCapital added most to Principia Biopharma Inc. Common Stock in Q1 2020, an estimated $5.5M increase.
  • Samsara BioCapital's biggest Q1 2020 reduction was SpringWorks Therapeutics, cutting an estimated $920K.
  • Samsara BioCapital's ten largest holdings make up 76% of its $174M portfolio in Q1 2020.
  • Samsara BioCapital opened 9 new positions and closed 0 in Q1 2020.
  • Samsara BioCapital's portfolio value fell 17% quarter-over-quarter to $174M.

Based on Samsara BioCapital's 13F filing for Q1 2020, filed 15 May 2020.